Advisors Asset Management Inc. Has $1.90 Million Stock Holdings in Masimo Co. (NASDAQ:MASI)

Advisors Asset Management Inc. lifted its stake in Masimo Co. (NASDAQ:MASI) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,216 shares of the medical equipment provider’s stock after acquiring an additional 501 shares during the quarter. Advisors Asset Management Inc.’s holdings in Masimo were worth $1,895,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. NBC Securities Inc. increased its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the period. Fifth Third Bancorp boosted its position in shares of Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after acquiring an additional 98 shares during the period. Oak Thistle LLC grew its stake in shares of Masimo by 5.2% in the second quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock valued at $262,000 after acquiring an additional 103 shares in the last quarter. GAMMA Investing LLC increased its position in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 111 shares during the period. Finally, HHM Wealth Advisors LLC raised its stake in Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MASI shares. BTIG Research lifted their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a research report on Wednesday, November 6th. Piper Sandler upped their price objective on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.00.

Masimo Stock Up 2.3 %

Shares of NASDAQ MASI opened at $172.96 on Monday. The stock has a 50-day moving average price of $143.48 and a two-hundred day moving average price of $127.94. Masimo Co. has a 12 month low of $91.60 and a 12 month high of $174.34. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market cap of $9.26 billion, a price-to-earnings ratio of 119.28 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.63 earnings per share. As a group, analysts forecast that Masimo Co. will post 4.04 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.